Chief Executive Officer

Dr. Madiyalakan is the CEO of OncoQuest Pharma USA Inc. and the Chairman of OncoQuest Pharmaceuticals Inc. listed in Korea (KOSDAQ 078590). Dr. Madi is also CEO and Director of Quest PharmaTech. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 25 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of several patents.


Chief Medical officer (OncoQuest Pharma USA)

Dr. Gupta has over 30 years of senior leadership experience in clinical development, medical and regulatory affairs focused on oncology drug development. Prior to joining OQP, Dr. Gupta was with Agenus Inc. for 2 years as Vice President of Regulatory and Pharmacovigilance.  Prior to joining Agenus, Dr. Gupta was with Sanofi and legacy company Rhone-Poulenc Rorer for 22 years.  Dr. Gupta has led several clinical trial programs in oncology that led to regulatory approvals with FDA, EMA and other agencies worldwide during his pharmaceutical industry career.  In a leadership role he has secured registration of 2 molecules, Eloxatin (oxaliplatin) for colorectal cancer and Jevtana (cabozitaxel) for advanced prostate cancer, with successful FDA, EMA, and other health agency interactions worldwide.  Dr. Gupta obtained his medical education in India followed by an internal medicine residency and oncology fellowship at the Ottawa University Hospitals, Ottawa, Canada.  He completed an additional year of advanced fellowship at the Indiana University Purdue University Medical Center at Indianapolis.


Vice President of Product Development

As the Vice President of Product Development, Mr. Woo is focusing on process, formulation and clinical development for products. Mr. Woo has been involved in successful clinical trial applications for more than six drug candidates during his tenure at Cytovax Biotechnologies Inc., AltaRex Corp., Biomira Research Inc., and Biomira Inc. Mr. Woo holds a Bachelor of Science degree in Pharmacy and a Master of Science degree in Pharmaceutical Sciences from the University of Alberta.


Senior Advisor to OncoQuest

Dr. Nicodemus is Founder, President and Chief Scientific Officer of AIT Strategies. He served as Chairman and Chief Scientific Officer of Advanced Immune Therapeutics, Inc. from 2008-2012. Dr. Nicodemus received undergraduate training at Harvard College and received his MD degree from Upstate Medical University in Syracuse, NY. He trained in Internal Medicine and completed a Research and Clinical fellowship in the laboratory of K Frank Austen, Department of Rheumatology and Clinical Immunology at Brigham and Women’s Hospital, Harvard Medical School, Boston. He held various research and clinical appointments at Harvard while pursuing a career in biotechnology. He has held executive positions at Pfizer, ImmuLogic, Diatide, AltaRex, United Therapeutics and Advanced Immune Therapeutics, Inc. He is a member of Alpha Omega Alpha and a fellow of the American College of Physicians.

%d bloggers like this: